SM
EVOK

Sabby Management’s Evoke Pharma EVOK Stock Holding History

Sabby Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-611
Closed -$48K – 167
2021
Q4 		$48K Buy
611
+42
+7% +$5.88K 0.01% 170
2021
Q3 		$107K Buy
569
+240
+73% +$40.5K 0.01% 158
2021
Q2 		$65K Buy
+329
New +$70.4K 0.01% 155
2021
Q1 		– Sell
-451
Closed -$168K – 171
2020
Q4 		$168K Buy
451
+296
+191% +$153K 0.03% 89
2020
Q3 		$105K Buy
+155
New +$98.9K 0.02% 115
2016
Q4 		– Sell
-443
Closed -$144K – 307
2016
Q3 		$144K Buy
+443
New +$203K 0.01% 282

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
WA
Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sabby Management's EVOK Position: Q1 2022 in Review

Sabby Management sold out of Evoke Pharma (EVOK) in Q1 2022, closing a stake of 611 shares — an estimated $48K sold.

Sabby Management first reported a position in EVOK in Q3 2016 and held it in 6 quarters. The position peaked at $168K in Q4 2020. 20 funds tracked by Wall St. Rank hold EVOK as of Q1 2022.

  • Sabby Management reported no remaining Evoke Pharma position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 611 Evoke Pharma shares in Q1 2022, an estimated $48K.
  • Sabby Management first reported a position in Evoke Pharma in Q3 2016 and held it in 6 quarters.
  • Sabby Management's Evoke Pharma position peaked at $168K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.